Oncolys BioPharma

Showing 1 posts of 1 posts found.

BMS licences phase II HIV compound festinavir

December 22, 2010
Research and Development BMS, Bristol-Myers Squibb, HIV, NRTI, Oncolys BioPharma, festinavir, nucleoside reverse transcriptase inhibitor

Bristol-Myers Squibb is to pay hundreds of millions of dollars to a Japanese biotech firm to get its hands on …

The Gateway to Local Adoption Series

Latest content